Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30540768 | 0.71 | IDO1 (0.58) | PIM1FGFR1MAP2K4 | |
| SCHEMBL31185796 | 0.69 | KDR (0.54) | FGFR1FGFR2FGFR3 | |
| SCHEMBL4037999 | 0.69 | TYRO3 (0.44) | — | |
| SCHEMBL15178476 | 0.67 | AXL (0.53) | PIM1FGFR1FGFR2MAP2K4 | |
| SCHEMBL29454447 | 0.66 | TYRO3 (0.42) | — | |
| SCHEMBL30968125 | 0.66 | TYRO3 (0.42) | — | |
| SCHEMBL16525458 | 0.66 | TYRO3 (0.42) | — | |
| SCHEMBL19970146 | 0.66 | TYRO3 (0.42) | — | |
| SCHEMBL4376800 | 0.66 | MAP2K4 (0.40) | PIM1CHEK1ACVR1FGFR1FGFR3 | |
| SCHEMBL4381597 | 0.66 | PDPK1 (0.46) | PIM1CHEK1ACVR1FGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018049152-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |